# Recurrent CIC-rearranged sarcoma of central nervous system: a clinicopathological case report

## TL;DR

This paper reports a rare case of CIC::DUX4 rearranged sarcoma in the brain, diagnosed with advanced techniques and highlighting its poor prognosis.

## Contribution

The study presents a rare case of primary CIC::DUX4 sarcoma in the CNS diagnosed using DNA methylation and multi-omics methods.

## Key findings

- CIC::DUX4 rearranged sarcoma was diagnosed in the central nervous system using DNA methylation classifiers.
- The tumor recurred in situ after chemoradiation therapy, indicating a poor prognosis.
- This case highlights the challenges in treating and managing this rare tumor type.

## Abstract

CIC-rearranged sarcoma (CRS) is a subgroup of small round blue cell tumors similar to Ewing’s sarcoma but lacking the EWSR1 gene translocation. It is characterized by a CIC gene rearrangement on chromosome 19q13, with the most common partner gene being DUX4. In 2021, the WHO classification of central nervous system tumors (5th edition) introduced a new pathological classification for CRS based on bone and soft tissue tumor classifications, categorizing it as mesenchymal non-meningeal epithelial tumors. Primary CIC::DUX4 rearrangement sarcoma in the central nervous system is extremely rare, with no established standard treatment and a very poor prognosis. Herein, we present a case of intracranial CIC::DUX4 rearrangement diagnosed using DNA methylation classifiers and multiple omics diagnosis techniques. We also document the disease progression after chemoradiation therapy and subsequent in situ recurrence.